Viridian Therapeutics, Inc.

VRDN

$17.04

+$0.18 (1.07%)

Closed

Loading chart...

IndexN/A

Market Cap1.45B

Enterprise Value2.48B

Income$-0.09B

Sales$0.00B

EmployeesN/A

P/E-5.09

P/S37.25

P/B3.65

P/C-9.53

EV/EBITDA-7.35

EV/SalesN/A

EPS (ttm)-3.35

EarningsN/A

Gross Margin100.00%

Oper. Margin-512.91%

Profit Margin-483.57%

Volume2.20M

Shs Outstand0.08B

Change1.07%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

May 611:13PMViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million(businesswire.com)

May 505:31PMViridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript(seekingalpha.com)04:05PMViridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock(businesswire.com)

Insider Trading

View All

Insider

Type

Price

Value

Date

Fairmount Healthcare Fund II GP LLC

Buy

454.5K

$22.00

$10.0M

Oct 23, 25

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

CEO: Stephen F. MahoneyEmployees: 143www.viridiantherapeutics.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	$302.00K	$314.00K	$1.77M	$2.96M	$1.05M	$4.46M	$8.39M	$4.00M
Cost of Revenue	N/A	N/A	N/A	N/A	$28.30M	N/A	$30.42M	$19.62M
Gross Profit	$302.00K	$314.00K	$1.77M	$2.96M	$-27.25M	$4.46M	$-22.04M	$-15.62M
Gross Margin	100.00%	100.00%	100.00%	100.00%	-2595.62%	100.00%	-262.76%	-390.21%
Operating Expenses	$299.34M	$254.76M	$136.08M	$82.69M	$83.13M	$46.44M	$11.05M	$10.91M
Operating Income	$-299.04M	$-254.45M	$-134.30M	$-79.73M	$-110.38M	$-41.98M	$-33.08M	$-26.53M
Operating Margin	-99018.21%	-81035.03%	-7579.23%	-2690.79%	-10512.38%	-941.02%	-394.51%	-662.80%
Net Income	$-269.95M	$-237.73M	$-129.87M	$-79.41M	$-110.72M	$-41.87M	$-32.70M	$-26.51M
Net Margin	-89387.09%	-75711.46%	-7329.23%	-2680.16%	-10544.29%	-938.65%	-389.97%	-662.30%
EPS (Basic)	$-3.98	$-5.31	$-3.91	$-6.66	$-31.20	$-20.31	$-16.57	$-20.66
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Viridian Therapeutics, Inc.

Insider Trading

Discover more